Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
China’s Food and Beverage Industry in Search of Methods to Shrink its Carbon Footprints
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
WIM 2022: Transcript of Fireside Chat of Biotech [1/2]
Aug 05, 2022 09:11 PM
WIM 2022: Transcript of Fireside Chat of Biotech [2/2]
Aug 05, 2022 09:08 PM
WIM2022: Transcripts of Blockchain Panel, Brilliant Future With Opportunities
Aug 05, 2022 02:06 AM